Publication details
Emicizumab v prevenci krvácení u pacientů s hemofilií A - první zkušenosti u dospělých pacientů
| Title in English | Emicizumab in the prevention of bleeding in patients with haemophilia - first experience in adult patients |
|---|---|
| Authors | |
| Year of publication | 2020 |
| Type | Article in Periodical |
| Magazine / Source | Remedia |
| MU Faculty or unit | |
| Citation | |
| Web | http://www.remedia.cz/Archiv-rocniku/Rocnik-2020/2-202/e-2T2-2V9.magissue.aspx |
| Keywords | emicizumab; HAVEN study; bleeding; laboratory monitoring |
| Description | The ability to use the bispecific monoclonal antibody emicizumab mimicking FVIII function in prophylactic treatment in patients wiht haemophilia A and Factor VIII inhibitor (FVIII) as well as in patients without FVIII inhibitor is a significant benefit in the management of these problematic cases. The article gives a brief review of the characteristics of emicizumab, its efficacy and safety, and presents case reports of two patients with FVIII inhibitor and one without inhibitor prophylactically treated with emicizumab, confirming the positive literature experience to date. |